OncoMatch/Clinical Trials/NCT05827523
Interval Cytoreductive Surgery With or Without HIPEC for Ovarian Cancer (FOCUS / KOV-HIPEC-04)
Is NCT05827523 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Cisplatin for ovarian cancer.
Treatment: Cisplatin — Primary stage III-IV epithelial ovarian cancer randomizing between interval cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy (HIPEC)
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Ovarian Cancer
Disease stage
Required: Stage FIGO STAGE III, FIGO STAGE IV (FIGO)
FIGO stage III-IV
Demographics
Prior therapy
Must have received: neoadjuvant chemotherapy
treated with three cycles of neoadjuvant chemotherapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05827523 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received neoadjuvant chemotherapy.
What disease stage is eligible?
Stage FIGO STAGE III or FIGO STAGE IV is required.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages